India Pharma Exports Surge to USD 16.14 Billion as Europe Demand Spikes
India's pharmaceutical exports grew 4.9% to USD 16.14 billion in H1 FY27, driven by a massive surge in European demand and emerging markets.
India's pharmaceutical sector has recorded a steady climb in its global footprint, with India pharma exports growth reaching USD 16,135.93 million during the first half of the financial year 2026–27 (April–September 2026). This represents a 4.90 per cent increase compared to the USD 15,382.85 million recorded during the same period in the previous fiscal year.
According to data released by the Pharmaceuticals Export Promotion Council of India (Pharmexcil), this growth was fueled by a consistent rise in the shipment of biologicals, drug formulations, surgical products, bulk drugs, and drug intermediates.
Quarterly Performance and Monthly Peaks
The growth trajectory remained positive throughout the period. In the second quarter (July–September 2026), outbound shipments grew by 3.05 per cent year-on-year, totaling USD 8.04 billion, up from USD 7.80 billion in the corresponding quarter of FY26.
September 2026 emerged as the standout month of the half-year window, recording the highest monthly export valuation at USD 2,744.05 million, a 4.68 per cent jump over September 2025.
Europe Leads the Charge
The European market has become a pivotal driver for the Indian pharmaceutical industry. Exports to Europe surged by 9.66 per cent, reaching USD 3,288.27 million. This means that over one-fifth (20.38 per cent) of India's total pharmaceutical exports in the first half of the year were destined for European shores.
Several European nations showed remarkable double-digit growth:
- Germany: 21.57 per cent increase
- Netherlands: 15.93 per cent increase
- France: 15.02 per cent increase
Diversifying Beyond the US
While exports to the United States saw a moderation, India successfully cushioned the impact through broad geographical diversification. The industry saw significant gains in other regions:
- ASEAN: Shipments climbed by 21.54 per cent.
- Latin America and the Caribbean: Deliveries rose by 16.58 per cent.
- Africa: Exports expanded by 6.48 per cent.
Product Breakdown: What's Moving?
The export volume was dominated by drug formulations and biologicals, which accounted for 73.84 per cent of the total and grew by 3.81 per cent. However, other segments showed even sharper growth rates:
- Bulk drugs and drug intermediates: Grew by 12.07 per cent.
- Surgical exports: Climbed by 9.53 per cent.
The Road Ahead: Innovation and Value
Namit Joshi, Chairman of Pharmexcil, emphasized that while India is known for affordable, high-quality medicines and large-scale production, the industry must now evolve. He urged companies to move up the value chain to become active partners in pharmaceutical innovation rather than just suppliers.
"This will require greater investment in research and development, technology transfer and co-development of complex generics, biosimilars and specialised therapies," Joshi stated, noting that Europe's strong research ecosystem provides a prime opportunity for such collaborations.
Adding to this, Bhavin Mehta, Vice Chairman of Pharmexcil, highlighted that the double-digit growth in bulk drugs reflects the depth of India's manufacturing capabilities. He suggested that continued investment in advanced manufacturing, regulatory preparedness, and quality systems would allow more Indian exporters, including MSMEs, to participate in the global market.
Pharmexcil has affirmed its commitment to working alongside the Government of India and regulatory bodies to improve market access, strengthen compliance, and push for innovation-led manufacturing.